Login to Your Account

Financings Roundup

Monday, December 12, 2011
• CeNeRx BioPharma Inc., of Research Triangle Park, N.C., said it completed a $4.85 million financing round from existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners, Pappas Ventures and Omega Funds. Proceeds will be used to complete the firm's ongoing Phase II trial of an improved formulation of TriRima, a reversible inhibitor of monoamine oxidase A, for use as a monotherapy in treatment-resistant depression.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription